Active	Status	Sponsor type	Region	Phase	Filter
6 Active 0 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
lescure, xavier
PREV-HOSPIT, NCT06822907: Immunogenicity and Safety PCV-20 of the Vaccine Administered During an Acute Febrile Illness in Adults	Not yet recruiting	4	1052	Europe	Early intervention, Delayed intervention	Centre Hospitalier Universitaire de Saint Etienne, Ministry of Health, France	Acute Febrile Illness, Pneumococcal Infections	01/27	01/28
MicrobioCOVID, NCT04669938: Role of the Microbiota in the Evolution of the SARS-CoV-2 Disease,COVID-19, in Hospitalized Patients	Recruiting	N/A	200	Europe	oropharyngeal and intestinal microbiota, host genotype, host immune factors, viral sequence	Assistance Publique - Hôpitaux de Paris	Covid19	12/21	08/22
SHASAR, NCT03716921: Short 3-week Antibiotic Treatment Versus 6 Weeks in Adults With Septic Arthritis of Native Joint	Completed	N/A	332	Europe	Short antibiotics treatment, 3-week antibiotic treatment	Assistance Publique - Hôpitaux de Paris	Septic Arthritis	08/23	01/24
CLOCEBA, NCT03248063: Non-inferiority Trial Comparing Cloxacillin vs Cefazolin in Methicillin-susceptible Staphylococcus Aureus Bacteremia	Active, not recruiting	N/A	315	Europe	Cloxacillin, Cefazolin	Assistance Publique - Hôpitaux de Paris	Bacteremia Due to Methicillin Susceptible Staphylococcus Aureus	06/24	12/24
SEVASAR, NCT04863547: Severity of the New UK SARS-Cov2 Variant in COVID-19 Infection	Recruiting	N/A	2200	Europe, RoW	Data collection	ANRS, Emerging Infectious Diseases	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)	04/21	05/21
Lescure, François-Xavier
CLOCEBA, NCT03248063: Non-inferiority Trial Comparing Cloxacillin vs Cefazolin in Methicillin-susceptible Staphylococcus Aureus Bacteremia	Active, not recruiting	N/A	315	Europe	Cloxacillin, Cefazolin	Assistance Publique - Hôpitaux de Paris	Bacteremia Due to Methicillin Susceptible Staphylococcus Aureus	06/24	12/24

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
lescure, xavier
PREV-HOSPIT, NCT06822907: Immunogenicity and Safety PCV-20 of the Vaccine Administered During an Acute Febrile Illness in Adults	Not yet recruiting	4	1052	Europe	Early intervention, Delayed intervention	Centre Hospitalier Universitaire de Saint Etienne, Ministry of Health, France	Acute Febrile Illness, Pneumococcal Infections	01/27	01/28
MicrobioCOVID, NCT04669938: Role of the Microbiota in the Evolution of the SARS-CoV-2 Disease,COVID-19, in Hospitalized Patients	Recruiting	N/A	200	Europe	oropharyngeal and intestinal microbiota, host genotype, host immune factors, viral sequence	Assistance Publique - Hôpitaux de Paris	Covid19	12/21	08/22
SHASAR, NCT03716921: Short 3-week Antibiotic Treatment Versus 6 Weeks in Adults With Septic Arthritis of Native Joint	Completed	N/A	332	Europe	Short antibiotics treatment, 3-week antibiotic treatment	Assistance Publique - Hôpitaux de Paris	Septic Arthritis	08/23	01/24
CLOCEBA, NCT03248063: Non-inferiority Trial Comparing Cloxacillin vs Cefazolin in Methicillin-susceptible Staphylococcus Aureus Bacteremia	Active, not recruiting	N/A	315	Europe	Cloxacillin, Cefazolin	Assistance Publique - Hôpitaux de Paris	Bacteremia Due to Methicillin Susceptible Staphylococcus Aureus	06/24	12/24
SEVASAR, NCT04863547: Severity of the New UK SARS-Cov2 Variant in COVID-19 Infection	Recruiting	N/A	2200	Europe, RoW	Data collection	ANRS, Emerging Infectious Diseases	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)	04/21	05/21
Lescure, François-Xavier
CLOCEBA, NCT03248063: Non-inferiority Trial Comparing Cloxacillin vs Cefazolin in Methicillin-susceptible Staphylococcus Aureus Bacteremia	Active, not recruiting	N/A	315	Europe	Cloxacillin, Cefazolin	Assistance Publique - Hôpitaux de Paris	Bacteremia Due to Methicillin Susceptible Staphylococcus Aureus	06/24	12/24